The DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.
Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs
Open accessAbstract
IMPORTANCE: Targeting oncogenic drivers (genomic alterations critical to cancer development and maintenance) has transformed the care of patients with lung adenocarcinomas. The Lung Cancer Mutation Consortium was formed to perform multiplexed assays testing adenocarcinomas of the lung for drivers in 10 genes to enable clinicians to select targeted treatments and enroll patients into clinical trials. OBJECTIVES: To determine the frequency of oncogenic drivers in patients with lung adenocarcinomas and to use the data to select treatments targeting the identified driver(s) and measure survival. DESIGN, SETTING, AND PARTICIPANTS: From 2009 through 2012, 14 sites in the United States enrolled patients with metastatic lung adenocarcinomas and a performance status of 0 through 2 and tested their tumors for 10 drivers. Information was collected on patients, therapies, and survival. INTERVENTIONS: Tumors were tested for 10 oncogenic drivers, and results were used to select matched targeted therapies. MAIN OUTCOMES AND MEASURES: Determination of the frequency of oncogenic drivers, the proportion of patients treated with genotype-directed therapy, and survival. RESULTS: From 2009 through 2012, tumors from 1007 patients were tested for at least 1 gene and 733 for 10 genes (patients with full genotyping). An oncogenic driver was found in 466 of 733 patients (64%). Among these 733 tumors, 182 tumors (25%) had the KRAS driver; sensitizing EGFR, 122 (17%); ALK rearrangements, 57 (8%); other EGFR, 29 (4%); 2 or more genes, 24 (3%); ERBB2 (formerly HER2), 19 (3%); BRAF, 16 (2%); PIK3CA, 6 (<1%); MET amplification, 5 (<1%); NRAS, 5 (<1%); MEK1, 1 (<1%); AKT1, 0. Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%). The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy (propensity score-adjusted hazard ratio, 0.69 [95% CI, 0.53-0.9], P = .006). CONCLUSIONS AND RELEVANCE: Actionable drivers were detected in 64% of lung adenocarcinomas. Multiplexed testing aided physicians in selecting therapies. Although individuals with drivers receiving a matched targeted agent lived longer, randomized trials are required to determine if targeting therapy based on oncogenic drivers improves survival. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01014286.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 of 15 cited sources checked · 0 supported · 0 flagged
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“2 or more genes, 24 (3%)”
- Also stated in: § Results · plain
“we found drivers in 2 genes in 24 tumors (3%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 24Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 190 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years (IQR, 1.96-7.70); the 248 with a driver and no targeted therapy, 2.5 years (P < .001”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ERBB2 (formerly HER2), 19 (3%)”
- Also stated in: § Results · plain
“The frequencies of ERBB2 (all exon 20 insertions) were 3% (19 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median survival was 3.5 years (interquartile range [IQR], 1.96-7.70) for the 260 patients with an oncogenic driver and genotype-directed therapy compared with 2.4 years (IQR, 0.88-6.20) for the 318 patients with any oncogenic driver(s) who did not receive genotype-directed therapy”
- Also stated in: § Results · plain
“The 260 patients with an oncogenic driver and treatment with a targeted agent had a median survival of 3.5 years; the 318 patients with a driver and no targeted therapy, 2.4 years”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“ALK rearrangements, 57 (8%)”
- Also stated in: § Results · plain
“ALK rearrangements occurred in 57 of 733 specimens (8%).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“An oncogenic driver was found in 466 of 733 patients (64%).”
- Also stated in: § Results · plain
“Among the 733 specimens tested for all 10 genes, 466 (64% [95% CI, 60%-67%) had an oncogenic driver”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Among these 733 tumors, 182 tumors (25%) had the KRAS driver”
- Also stated in: § Results · plain
“KRAS mutations were the most frequent, found in 182 of 733 specimens (25%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Overall, 28% (95% CI, 24%-30%) of eligible patients and 44% of individuals with drivers detected received a targeted therapy.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The frequencies of drivers in the 1007 specimens in which at least 1 gene was assessed are presented in Table 2 and mirror the results with the patients’ tumors with full genotyping.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“BRAF, 16 (2%)”
- Also stated in: § Results · plain
“BRAF mutations were 2% (16 of 733 specimens)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Strength:plain· not yet calibratedn = 733Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Also stated in: § Results · plain
- The quote only partly states this claim. 1
- It may state two separate claims as one. 8
- Probably not a substantial claim. 9
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“other EGFR, 29 (4%)”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > RESULTS
Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesThe quote only partly states this claim.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC characterized at least 1 gene for 91% (1007 of 1102 patients) of eligible patients with genotyping of all 10 genes in 66% (733 of 1102 patients).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The median potential follow-up was 2.0 years.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 938Tests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Of the 175 patients (83%) with EGFR(s) mutations, 146 were treated with targeted therapy: 130 with erlotinib alone, and 16 with another EGFR inhibitor alone or in combination.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Results
Strength:plain· not yet calibratedn = 175Tests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Patients in the driver + treatment group had a 5% better performance status, a 3-year lower median age, and were more likely to be never smokers (Table 1); factors that could lead to an improved prognosis.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Multiplexed testing aided physicians in selecting therapies.”
- Also stated in: § Conclusions · plain
“Multiplexed testing aided physicians in selecting therapies and patients for targeted trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Conclusions · plain
None of the sources cited for this claim have been checked yet.
In the paper
“Testing for somatic mutations in the epidermal growth factor receptor (EGFR) gene4-6 and rearrangements of the anaplastic lymphoma kinase (ALK) gene7 is now routine.8”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Abstract > CONCLUSIONS AND RELEVANCE
What the sources say
- Not checked yetcites [4] Lynch TJ Bell DW Sordella R Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small cell lung cancer to gefitinib N Engl J Med 2004 350 21 2129 2139 15118073
- Not checked yetcites [5] Paez JG Jänne PA Lee JC EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 2004 304 5676 1497 1500 15118125
- Not checked yetcites [6] Pao W Miller V Zakowski M EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad SciUS A 2004 101 36 13306 13311 PMC516528 15329413
- Not checked yetcites [7] Kwak EL Bang YJ Camidge DR Anaplastic lymphoma kinase inhibition in non-small cell lung cancer N Engl J Med 2010 363 18 1693 1703 20979469 PMC3014291
- Not checked yetcites [8] National Comprehensive Cancer Network NCCN clinical practice guidelines in oncology 2014 http://www.nccn.org/professionals/physician_gls/f_guidelines.asp. Accessed April 21
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Adenocarcinoma was centrally confirmed.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Patients
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC clinical committee chairs reviewed the records of each patient with an oncogenic driver and the targeted agent administered to verify that the treatment was directed against that driver(s) detected in the patient’s tumor.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“With the proposed sample size of 1000, the half-width of the 95% CI is less than 5% if the oncogenic driver rate is less than 40%.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The decision to recommend a targeted therapy to a patient with a tumor harboring an oncogenic driver was left to the treating physician.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The knowledge-based confounding variables adjusted in the propensity model were sex, age at enrollment, performance status, smoking history, stage at diagnosis, prior therapy (surgery, chest radiotherapy, or chemotherapy), and elapsed time from metastatic disease diagnosis to study enrollment (years).”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Statistical Methods
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Criteria for specimen adequacy were not prespecified.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
None of the sources cited for this claim have been checked yet.
In the paper
“The LCMC effort differs from other genomic characterization efforts, like the Cancer Genome Atlas that studied patients with localized disease and obtained tissues exclusively from resection specimens.35-40”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
What the sources say
- Not checked yetcites [35] Weir BA Woo MS Getz G Characterizing the cancer genome in lung adenocarcinoma Nature 2007 450 7171 893 898 17982442 PMC2538683
- Not checked yetcites [36] Barletta JA Perner S Iafrate AJ Clinical significance of TTF-1 protein expression and TTF-1 gene amplification in lung adenocarcinoma J Cell Mol Med 2009 13 8B 1977 1986 19040416 PMC2830395
- Not checked yetcites [37] Hammerman PS Sos ML Ramos AH Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer Cancer Discov 2011 1 1 78 89 22328973 PMC3274752
- Not checked yetcites [38] Cancer Genome Atlas Research Network Comprehensive genomic characterization of squamous cell lung cancers Nature 2012 489 7417 519 525 [published online September 27, 2012] 22960745 PMC3466113
- Not checked yetcites [39] D’Angelo SP Janjigian YY Ahye N Distinct clinical course of EGFR-mutant resected lung cancers: results of testing of 1118 surgical specimens and effects of adjuvant gefitinib and erlotinib J Thorac Oncol 2012 7 12 1815 1822 23154553
- Not checked yetcites [40] Peifer M Fernández-Cuesta L Sos ML Integrative genome analyses identify key somatic driver mutations of small cell lung cancer Nat Genet 2012 44 10 1104 1110 22941188 PMC4915822
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The LCMC pathologists shared blinded samples, with a positive sample included for all 10 drivers.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Methods > Interventions
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The multiplexed genotyping platforms made effective use of patient tissue and identified actionable drivers sooner, giving patient’s earlier access to therapies or trials.”
§ Using Multiplexed Assays of Oncogenic Drivers in Lung Cancers to Select Targeted Drugs > Discussion
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The presence of EGFR mutations defines a specific molecular subgroup of NSCLC (~15% of Caucasian patients with adenocarcinomas) [37, 38] that respond to an EGFR TKI in over 60% of patients (Table 1).”
From A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives (2015) · cites this paper as [38]
In the citing paper
“Somatic mutations in the kinase domain of the epidermal growth factor receptor (EGFR) gene are detected in approximately 40% and 17% of lung adenocarcinoma in Asians1 and in Caucasians,2 respectively.”
From Not all epidermal growth factor receptor mutations in lung cancer are created equal: Perspectives for individualized treatment strategy (2016) · cites this paper as [2]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
MET amplification count differs within the full-genotyping results
MajorMET amplification is reported in 5 of the 733 fully genotyped tumors, but the later count assigns MET amplification to 8 double-driver tumors in that group.
“Amplification of MET (MET/ CEP7 >2.2) was found in 5 of 733 patients’ tumors (<1%).”
“In the full genotyping group, we found drivers in 2 genes in 24 tumors (3%). Of these 24 specimens, 20 (83%) included either a mutation in PIK3CA (n = 12) or MET amplification (n = 8).”
Targeted-therapy percentage is overstated
MinorThe reported 275 of 1007 patients is 27.3%, which rounds to 27%, not 28%.
Reported 28 · recomputed 27.308838
“Results were used to select a targeted therapy or trial in 275 of 1007 patients (28%).”
Supplementary figure number conflicts for the exclusion analysis
MinorThe Results attribute the analysis excluding EGFR- and ALK-positive cancers to eFigure 6, whereas the Discussion attributes that analysis to eFigure 4.
“We also recomputed the survival data excluding individuals with EGFR- and ALK-positive cancers. The 49 patients with oncogenic drivers other than EGFR or ALK who received a targeted therapy had a median survival of 4.9 years compared with the 678 with (318 patients) or without (360 patients) a driver identified, but not receiving a targeted agent, whose median survivals were 2.4 years with a driver (IQR, 0.88-6.20) and 2.1 years without (P = .14; eFigure 6 in the Supplement).”
“survival analyses excluding these patients revealed that individuals with other drivers treated with targeted therapies still had an observed 2.5-year improvement in median survival over those who did not receive targeted therapy (eFigure 4 in the Supplement).”
Citations
Cites
Siegel, R., Ma, J., Zou, Z., & Jemal, A. (2014) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21208 · Cited by 11,499
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationGefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
Mok, T. S., Wu, Y.-L., Thongprasert, S., Yang, C.-H., Chu, D.-T., Saijo, N., Sunpaweravong, P., Han, B., Margono, B., Ichinose, Y., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810699 · Cited by 8,261
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
Soda, M., Choi, Y. L., Enomoto, M., Takada, S., Yamashita, Y., Ishikawa, S., Fujiwara, S.-I., Watanabe, H., Kurashina, K., Hatanaka, H., et al. (2007) · Nature · doi:10.1038/nature05945 · Cited by 5,439
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
Kwak, E. L., Bang, Y., Camidge, D. R., Shaw, A. T., Solomon, B., Maki, R. G., Ou, S. I., Dezube, B. J., Janne, P. A., Costa, D. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1006448 · Cited by 4,477
Self-citationPao, W., Miller, V., Zakowski, M., Doherty, J., Politi, K., Sarkaria, I., Singh, B., Heelan, R., Rusch, V., Fulton, L., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0405220101 · Cited by 4,338
Self-citationComprehensive genomic characterization of squamous cell lung cancers
The Cancer Genome Atlas Research Network (2012) · Nature · doi:10.1038/nature11404 · Cited by 3,994
Self-citationSequist, L. V., Yang, J. C.-H., Yamamoto, N., O'Byrne, K., Hirsh, V., Mok, T., Geater, S. L., Orlov, S., Tsai, C.-M., Boyer, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.44.2806 · Cited by 3,228
Self-citationFirst-Line Crizotinib versus Chemotherapy in ALK -Positive Lung Cancer
Solomon, B. J., Mok, T., Kim, D.-W., Wu, Y.-L., Nakagawa, K., Mekhail, T., Felip, E., Cappuzzo, F., Paolini, J., Usari, T., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1408440 · Cited by 3,190
Flagged first, then by citations
Cited by
Sorted by citations
Items 501–600 of 1,000
Ocaña, A., Ethier, J.-L., Díez-González, L., Corrales‐Sánchez, V., Srikanthan, A., Gascón-Escribano, M. J., Templeton, A. J., Vera-Badillo, F., Šeruga, B., Niraula, S., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5946 · Cited by 32
Kim, E. Y., Cho, E. N., Park, H. S., Kim, A., Hong, J. Y., Lim, S., Youn, J. P., Hwang, S. Y., & Chang, Y. S. (2016) · BMC Cancer · doi:10.1186/s12885-016-2049-z · Cited by 31
Siegfried, J. M., Farooqui, M., Rothenberger, N. J., Đačić, S., & Stabile, L. P. (2017) · Oncotarget · doi:10.18632/oncotarget.16030 · Cited by 31
Treating ALK-positive non-small cell lung cancer
Ziogas, D. C., Tsiara, A., Tsironis, G., Lykka, M., Liontos, M., Bamias, A., & Dimopoulos, M. A. (2018) · Annals of Translational Medicine · doi:10.21037/atm.2017.11.34 · Cited by 30
Signorovitch, J., Zhou, Z., Ryan, J., Anhorn, R., & Chawla, A. (2018) · Journal of Medical Economics · doi:10.1080/13696998.2018.1549056 · Cited by 31
Zhou, J., Ding, N., Xu, X., Zhang, Y., Ye, M., Li, C., & Hu, J. (2020) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758835920936090 · Cited by 31
Role of Farnesoid X Receptor in the Pathogenesis of Respiratory Diseases
Wu, J., Chen, J., & Chen, J. (2020) · Canadian Respiratory Journal · doi:10.1155/2020/9137251 · Cited by 31
A molecular pathological study of four cases of ciliated muconodular papillary tumors of the lung
Kataoka, T., Okudela, K., Matsumura, M., Mitsui, H., Suzuki, T., Koike, C., Sawazumi, T., Umeda, S., Tateishi, Y., Yamanaka, S., et al. (2018) · Pathology International · doi:10.1111/pin.12664 · Cited by 31
John, A. K., Shah, R. A., Wong, W. B., Schneider, C. E., & Alexander, M. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0864 · Cited by 31
Management of Brain Metastases
Collier, E. F., Chiang, V., & Goldberg, S. B. (2021) · Current cancer research · doi:10.1007/978-3-030-74028-3_6 · Cited by 32
Drilon, A., Schoenfeld, A. J., Arbour, K. C., Litvak, A., Ni, A., Montecalvo, J., Yu, H. A., Panora, E., Ahn, L., Kennedy, M., et al. (2019) · Molecular Case Studies · doi:10.1101/mcs.a003665 · Cited by 31
Self-citationLevy, B. P., Chioda, M. D., Herndon, D., Longshore, J. W., Mohamed, M., Ou, S. I., Reynolds, C. H., Singh, J. R., Wistuba, I. I., Bunn, P. A., et al. (2015) · The Oncologist · doi:10.1634/theoncologist.2015-0114 · Cited by 30
Self-citationThe potential of neurotrophic tyrosine kinase (NTRK) inhibitors for treating lung cancer
Passiglia, F., Caparica, R., Giovannetti, E., Giallombardo, M., Listì, A., Diana, P., Cirrincione, G., Caglevic, C., Raez, L. E., Russo, A. D., et al. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1152261 · Cited by 30
Li, B. T., Lou, E., Hsu, M., Yu, H. A., Naidoo, J., Zauderer, M. G., Sima, C. S., Johnson, M. L., Daras, M., DeAngelis, L. M., et al. (2016) · PLoS ONE · doi:10.1371/journal.pone.0146063 · Cited by 30
Self-citationCheema, P. K., Raphael, S. J., El-Maraghi, R. H., Li, J., McClure, R. F., Zibdawi, L., Chan, A., Victor, J. C., Dolley, A., & Dziarmaga, A. (2017) · Current Oncology · doi:10.3747/co.24.3266 · Cited by 30
Chalmers, A. W., Cannon, L. A., & Akerley, W. (2018) · The Oncologist · doi:10.1634/theoncologist.2018-0296 · Cited by 31
Craig, M., Kaveh, K., Woosley, A. N., Brown, A. S., Goldman, D. A., Eton, E. O., Mehta, R. M., Dhawan, A., Arai, K., Rahman, M. M., et al. (2019) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1007278 · Cited by 30
A novel circular RNA circENTPD7 contributes to glioblastoma progression by targeting ROS1
Zhu, F., Cheng, C., qin, H., Wang, H., & Yu, H. (2020) · Cancer Cell International · doi:10.1186/s12935-020-01208-9 · Cited by 30
He, M. Y., Han, Y., Cai, C., Liu, P., Chen, Y., Shen, H., Xu, X., & Zeng, S. (2021) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.16416 · Cited by 31
Joshi, A., Mishra, R., Desai, S., Chandrani, P., Kore, H., Sunder, R., Hait, S., Iyer, P. S., Trivedi, V., Choughule, A. B., et al. (2021) · Oncotarget · doi:10.18632/oncotarget.27905 · Cited by 30
Non-genetic adaptive resistance to KRASG12C inhibition: EMT is not the only culprit
Ning, W., Marti, T. M., Dorn, P., & Peng, R.-W. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.1004669 · Cited by 29
The possibility of clinical sequencing in the management of cancer
Kou, T., Kanai, M., Matsumoto, S., Okuno, Y., & Muto, M. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw018 · Cited by 30
The End of Nihilism: Systemic Therapy of Advanced Non–Small Cell Lung Cancer
Ernani, V., Steuer, C. E., & Jahanzeb, M. (2016) · Annual Review of Medicine · doi:10.1146/annurev-med-042915-102442 · Cited by 29
Recent advances in the management of non-small cell lung cancer
Shojaee, S., & Nana-Sinkam, P. S. (2017) · F1000Research · doi:10.12688/f1000research.11471.1 · Cited by 29
Zhou, J., Zhao, C., Zhao, J., Wang, Q., Chu, X., Li, J., Zhou, F., Ren, S., Li, X., Su, C., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13035 · Cited by 29
Fernandes, G., Jacob, M., Martins, N. A., Moura, C. S., Guimarães, S., Reis, J. P., Justino, A., Pina, M. J., Cirnes, L., Sousa, C., et al. (2019) · Cancers · doi:10.3390/cancers11091229 · Cited by 29
Yokose, T., Kitago, M., Matsuda, S., Sasaki, Y., Masugi, Y., Nakamura, Y., Shinoda, M., Yagi, H., Abe, Y., Oshima, G., et al. (2020) · Cancer Science · doi:10.1111/cas.14425 · Cited by 28
Ji, X., Liu, Y., Mei, F., Li, X., Zhang, M., Yao, B., Wu, R., You, J., & Pei, F. (2021) · Scientific Reports · doi:10.1038/s41598-021-93484-2 · Cited by 29
Natural Compounds Targeting Major Signaling Pathways in Lung Cancer
Kumar, S., Sharma, A. K., Lalhlenmawia, H., & Kumar, D. (2021) · Springer eBooks · doi:10.1007/978-981-33-6827-9_37 · Cited by 29
Hellyer, J. A., White, M. N., Gardner, R. M., Cunanan, K. M., Padda, S. K., Das, M. S., Ramchandran, K. J., Neal, J. W., & Wakelee, H. A. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.09.004 · Cited by 30
Fukui, T., TACHIHARA, M. Y., Nagano, T., & Kobayashi, K. (2022) · Cancers · doi:10.3390/cancers14051184 · Cited by 31
Kringelbach, T. M., Højgaard, M., Rohrberg, K. S., Spanggaard, I., Laursen, B. E., Ladekarl, M. B., Haslund, C. A., Harsløf, L. B. S., Belcaid, L., Gehl, J., et al. (2023) · BMC Cancer · doi:10.1186/s12885-023-10632-9 · Cited by 29
Yang, H., Zhou, Z. X., Lin, L. W., Yang, M., Li, C., Li, Z., Yu, X., Lizaso, A., Han‐Zhang, H., Li, B., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.08.009 · Cited by 30
EGFRmutation and lobar location of lung adenocarcinoma
Tseng, C., Chen, K., Hsu, K.-H., Tseng, J., Ho, C., Hsia, T., Su, K., Wu, M., Chiu, K.-L., Liu, C.-M., et al. (2015) · Carcinogenesis · doi:10.1093/carcin/bgv168 · Cited by 28
Self-citationChen, X., Zhang, Y., Lu, J., Xu, C., Liang, J., Wang, F., Sun, W., Fang, S., Yuan, J., Wang, H., et al. (2017) · Translational Oncology · doi:10.1016/j.tranon.2016.11.009 · Cited by 28
DiBardino, D. M., Rawson, D. W., Saqi, A., Heymann, J. J., Pagan, C. A., & Bulman, W. A. (2017) · CytoJournal · doi:10.4103/1742-6413.202602 · Cited by 28
Targeted Therapy for Patients With Metastatic Non–Small Cell Lung Cancer
Reckamp, K. L. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0046 · Cited by 28
Kato, Y., Ninomiya, K., Ohashi, K., Tomida, S., Makimoto, G., Watanabe, H., Kudo, K., Matsumoto, S., Umemura, S., Goto, K., et al. (2018) · Cancer Science · doi:10.1111/cas.13752 · Cited by 28
Targeted Molecular Treatments in Non-Small Cell Lung Cancer: A Clinical Guide for Oncologists
Bui, K. T., Cooper, W. A., Kao, S., & Boyer, M. J. (2018) · Journal of Clinical Medicine · doi:10.3390/jcm7080192 · Cited by 29
Lim, J. U., Yeo, C. D., Kang, H. S., Park, C. K., Kim, J. S., Kim, J., Kim, S. J., & Lee, S. H. (2019) · Scientific Reports · doi:10.1038/s41598-019-41289-9 · Cited by 28
Zimmer, K., Kocher, F., Spizzo, G., Salem, M. E., Gastl, G. A., & Seeber, A. (2019) · Computational and Structural Biotechnology Journal · doi:10.1016/j.csbj.2019.03.012 · Cited by 28
Yokoyama, T., Yoshioka, H., Fujimoto, D., Demura, Y., Hirano, K., Kawai, T., Kagami, R., Washio, Y., Ishida, T., Kogo, M., et al. (2019) · Lung Cancer · doi:10.1016/j.lungcan.2019.03.030 · Cited by 28
Zheng, C. J., Li, X., Ren, Y., Yin, Z., & Zhou, B. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2020.00030 · Cited by 28
Bonanno, L., Pavan, A., Ferro, A., Calvetti, L., Frega, S., Pasello, G., Aprile, G., Guarneri, V., Conte, P., & (ROV), O. B. O. R. O. V. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0148 · Cited by 28
Singh, J., Luqman, S., & Meena, A. (2020) · Food and Chemical Toxicology · doi:10.1016/j.fct.2020.111592 · Cited by 25
Next Generation Sequencing in Non-Small Cell Lung Cancer: Pitfalls and Opportunities
Lazzari, C., Bulotta, A., Cangi, M. G., Bucci, G., Pecciarini, L., Bonfiglio, S., Lorusso, V., Ippati, S., Arrigoni, G., Grassini, G., et al. (2020) · Diagnostics · doi:10.3390/diagnostics10121092 · Cited by 28
Kolesar, J., Peh, K. H., Thomas, L., Baburaj, G., Mukherjee, N., Kantamneni, R., Lewis, S. C., Pai, A., Udupa, K., Kumar, N. A. N., et al. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01534-8 · Cited by 32
Ionescu, D. N., Stockley, T. L., Banerji, S. O., Couture, C., Mather, C. A., Xu, Z., Blais, N., Cheema, P. K., Chu, Q. S.-C., Melosky, B. L., et al. (2022) · Current Oncology · doi:10.3390/curroncol29070396 · Cited by 28
High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma
Mahmood, K., Jampani, P., Clarke, J. M., Wolf, S. P., Wang, X., Wahidi, M. M., Giovacchini, C. X., Dorry, M., Shofer, S. L., Shier, J., et al. (2023) · CHEST Journal · doi:10.1016/j.chest.2023.01.019 · Cited by 28
Cardiac Interventions in Patients With Active, Advanced Solid and Hematologic Malignancies
Leong, D. P., Cirne, F., Aghel, N., Vila, R. C. B., Cavalli, G. D., Ellis, P. M., Healey, J. S., Whitlock, R. P., Khalaf, D., Mian, H. S., et al. (2023) · JACC CardioOncology · doi:10.1016/j.jaccao.2023.05.008 · Cited by 30
Suda, K., Kim, J., Murakami, I., Rozeboom, L. M., Shimoji, M., Shimizu, S., Rivard, C. J., Mitsudomi, T., Tan, A. C., & Hirsch, F. R. (2018) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.05.039 · Cited by 30
Kerr, K. M., Bubendorf, L., López‐Ríos, F., Khalil, F. K., Roy‐Chowdhuri, S., Joubert, P., Hartmann, A., Guerini‐Rocco, E., Yatabe, Y., Hofman, P. M., et al. (2023) · Histopathology · doi:10.1111/his.15078 · Cited by 27
Prognostic and predictive biomarkers for targeted therapy in NSCLC: for whom the bell tolls?
Passiglia, F., Bronte, G., Castiglia, M., Listì, A., Calò, V., Toia, F., Cicero, G., Fanale, D., Rizzo, S., Bazan, V., et al. (2015) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2015.1071348 · Cited by 29
Genomic Testing in Lung Cancer: Past, Present, and Future
Mascaux, C., Tsao, M., & Hirsch, F. R. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2017.7019 · Cited by 27
Novel approaches against epidermal growth factor receptor tyrosine kinase inhibitor resistance
Heydt, C., Michels, S. Y. F., Thress, K. S., Bergner, S., Wolf, J., & Buettner, R. (2018) · Oncotarget · doi:10.18632/oncotarget.24624 · Cited by 27
Karim, N. A., & Kelly, K. L. (2019) · The Oncologist · doi:10.1634/theoncologist.2018-0112 · Cited by 26
Validation of Immunohistochemistry for the Detection of BRAF V600E-Mutated Lung Adenocarcinomas
Gow, C., Hsieh, M., Lin, Y., Liu, Y., & Shih, J. (2019) · Cancers · doi:10.3390/cancers11060866 · Cited by 28
Feasibility of next‐generation sequencing test for patients with advanced NSCLC in clinical practice
Ariyasu, R., Uchibori, K., Ninomiya, H., Ogusu, S., Tsugitomi, R., Manabe, R., Sakamaoto, H., Tozuka, T., Yoshida, H., Amino, Y., et al. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13786 · Cited by 27
Shin, D. H., Kim, S. H., Choi, M., Bae, Y., Han, C., Choi, B. K., Kim, S. S., & Han, J. (2021) · Oncogene · doi:10.1038/s41388-021-02097-6 · Cited by 28
Genomic and biological study of fusion genes as resistance mechanisms to EGFR inhibitors
Kobayashi, Y., Oxnard, G. R., Cohen, E. F., Mahadevan, N. R., Alessi, J. V., Hung, Y. P., Bertram, A. A., Heppner, D. E., Ribeiro, M. F. S. A., Sacardo, K. P., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33210-2 · Cited by 26
Villaruz, L. C., Socinski, M. A., & Weiss, J. M. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1124167 · Cited by 27
Self-citationManolakos, P., & Ward, L. D. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13061010 · Cited by 25
Recent advances in endobronchial ultrasound-guided transbronchial needle aspiration
Nakajima, T., Yasufuku, K., Fujiwara, T., & Yoshino, I. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.02.002 · Cited by 27
Next-generation sequencing in NSCLC and melanoma patients: a cost and budget impact analysis
van Amerongen, R. A., Retèl, V. P., Coupé, V. M. H., Nederlof, P. M., Vogel, M. J., & van Harten, W. H. (2016) · ecancermedicalscience · doi:10.3332/ecancer.2016.684 · Cited by 27
Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma
Thakur, M. K., & Wozniak, A. J. (2017) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s104207 · Cited by 27
Ni, Y., Liu, B., Ye, X., Fan, W., Bi, J., Yang, X., Huang, G., Li, W., Wang, J., Han, X., et al. (2019) · CardioVascular and Interventional Radiology · doi:10.1007/s00270-018-02153-x · Cited by 27
Reina, C., Šabanović, B., Lazzari, C., Gregorc, V., & Heeschen, C. (2024) · Translational research · doi:10.1016/j.trsl.2024.05.014 · Cited by 27
Precision medicine in oncology drug development: a pharma perspective
Hollingsworth, S. J. (2015) · Drug Discovery Today · doi:10.1016/j.drudis.2015.10.005 · Cited by 26
Overman, M. J., Morris, V. K., Kee, B. K., Fogelman, D. R., Xiao, L., Eng, C., Dasari, A. N., Shroff, R. T., Mazard, T., Shaw, K. R. M., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw073 · Cited by 26
New Targets in Non–Small Cell Lung Cancer
Park, S. J., More, S., Murtuza, A., Woodward, B. D., & Husain, H. (2016) · Hematology/Oncology Clinics of North America · doi:10.1016/j.hoc.2016.08.010 · Cited by 26
Zhu, C., Lian, X., Bi, Y.-H., Hu, C., Liang, Y.-W., & Li, Q. (2018) · Clinica Chimica Acta · doi:10.1016/j.cca.2018.05.042 · Cited by 26
Pujol, J.-L., Coffy, A., Camerini, A., Kotsakis, A. P., Mencoboni, M., Gusella, M., Pasini, F., Pezzuto, A., Banna, G. L., Bilir, C., et al. (2019) · PLoS ONE · doi:10.1371/journal.pone.0220988 · Cited by 26
Furuya, N., Matsumoto, S., Kakinuma, K., Morikawa, K., Inoue, T., Saji, H., Goto, K., & Mineshita, M. (2020) · Cancer Science · doi:10.1111/cas.14714 · Cited by 26
Nana, F. A., & Ocak, S. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13091478 · Cited by 26
Role of Immune Checkpoint Inhibitor Therapy in Advanced EGFR-Mutant Non-Small Cell Lung Cancer
Wiest, N. E., Majeed, U., Seegobin, K., Zhao, Y., Lou, Y., & Manochakian, R. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.751209 · Cited by 26
Lin, Z., Li, Y., Tang, S., Deng, Q., Jiang, J., & Zhou, C. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107282 · Cited by 26
Cagle, P. T., Sholl, L. M., Lindeman, N. I., Alsabeh, R., Divaris, D. X. G., Foulis, P., Lee, G., Neal, J. W., Nowak, J. A., Yu, P. P., et al. (2013) · Archives of Pathology & Laboratory Medicine · doi:10.5858/arpa.2013-0232-cp · Cited by 25
Integrative omics analyses broaden treatment targets in human cancer
Sengupta, S., Sun, S. Q., Huang, K., Oh, C., Bailey, M. H., Varghese, R., Wyczalkowski, M. A., Ning, J., Tripathi, P., McMichael, J. F., et al. (2018) · Genome Medicine · doi:10.1186/s13073-018-0564-z · Cited by 28
du Tertre, M. C., Marques, M., Tremblay, L., Bouchard, N., Diaconescu, R., Blais, N., Couture, C., Pelsser, V., Wang, H., Higenell, V., et al. (2019) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-19-0105 · Cited by 26
History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer
Ariga, S. (2023) · Journal of Clinical Medicine · doi:10.3390/jcm12103391 · Cited by 26
Salgia, R. (2016) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2016.1181545 · Cited by 25
Clinical utility of circulating cell-free DNA in advanced colorectal cancer
Pereira, A. A. L., Morelli, M. P., Overman, M. J., Kee, B. K., Fogelman, D. R., Vilar, E., Shureiqi, I., Raghav, K. P. S., Eng, C., Manuel, S., et al. (2017) · PLoS ONE · doi:10.1371/journal.pone.0183949 · Cited by 25
Therapeutic strategies for afatinib‐resistant lung cancer harboring HER 2 alterations
Torigoe, H., Shien, K., Takeda, T., Yoshioka, T., Namba, K., Sato, H., Suzawa, K., Yamamoto, H., Soh, J., Sakaguchi, M., et al. (2018) · Cancer Science · doi:10.1111/cas.13571 · Cited by 25
Alahmadi, A. A., Ardeshir‐Larijani, F., Fu, P., Cao, S., Lipka, M. B., Dowlati, A., & Bruno, D. S. (2020) · Clinical Lung Cancer · doi:10.1016/j.cllc.2020.08.004 · Cited by 26
Gruendner, J., Wolf, N., Tögel, L., Haller, F., Prokosch, H., & Christoph, J. (2020) · Journal of Medical Internet Research · doi:10.2196/19879 · Cited by 24
Mantilla, W. A., Sanabria‐Salas, M. C., Baldión, A. M., Sua, L. F., Gonzalez, D. M., & Lema, M. (2021) · JCO Global Oncology · doi:10.1200/go.21.00046 · Cited by 25
Popat, S., Hsia, T., Hung, J., Jung, H. A., Shih, J., Park, C., Lee, S. H., Okamoto, T., Ahn, H. K., Lee, Y. C., et al. (2022) · The Oncologist · doi:10.1093/oncolo/oyac022 · Cited by 25
Yang, L., Wei, S., Zhang, J., Hu, Q., Hu, W., Cao, M., Zhang, L., Wang, Y., Wang, P., & Wang, K. (2022) · Journal of Translational Medicine · doi:10.1186/s12967-022-03565-7 · Cited by 27
Personalized Cancer Monitoring Assay for the Detection of ctDNA in Patients with Solid Tumors
Zhao, J., Reuther, J., Scozzaro, K., Hawley, M., Metzger, E., Emery, M., Chen, I., Barbosa, M., Johnson, L., O’Connor, A., et al. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00670-1 · Cited by 29
MET in Non-Small-Cell Lung Cancer (NSCLC): Cross ‘a Long and Winding Road’ Looking for a Target
Spitaleri, G., Aliaga, P. T., Attili, I., Signore, E. D., Corvaja, C., Corti, C., Uliano, J., Passaro, A., & de Marinis, F. (2023) · Cancers · doi:10.3390/cancers15194779 · Cited by 24
Fiore, L. D., Brophy, M. T., Turek, S., Kudesia, V., Ramnath, N., Shannon, C., Ferguson, R. E., Pyarajan, S., Fiore, M., Hornberger, J. C., et al. (2016) · Biomarkers in Cancer · doi:10.4137/bic.s37548 · Cited by 25
Huang, C., Chen, B.-H., Chou, W., Yang, C., & Chang, J. W. (2018) · Journal of Thoracic Disease · doi:10.21037/jtd.2018.03.143 · Cited by 25
DeMaio, A. J., Clarke, J. M., Dash, R., Sebastian, S., Wahidi, M. M., Shofer, S. L., Cheng, G. Z., Li, X., Wang, X., & Mahmood, K. (2018) · Journal of Bronchology & Interventional Pulmonology · doi:10.1097/lbr.0000000000000534 · Cited by 26
Relationship of Driver Oncogenes to Long-Term Pemetrexed Response in Non–Small-Cell Lung Cancer
Liang, Y., Wakelee, H. A., & Neal, J. W. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.009 · Cited by 25
Rangachari, D., VanderLaan, P. A., Le, X., Folch, E. E., Kent, M. S., Gangadharan, S. P., Majid, A., Haspel, R. L., Joseph, L. J., Huberman, M. S., et al. (2015) · Cancer Treatment Communications · doi:10.1016/j.ctrc.2015.10.004 · Cited by 25
Value: The Next Frontier in Cancer Care
Goulart, B. H. L. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0174 · Cited by 24
Passaro, A., Lazzari, C., Karachaliou, N., Spitaleri, G., Pochesci, A., Catania, C., Rosell, R., & de Marinis, F. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s98347 · Cited by 24
Castiglione, R., Alidousty, C., Holz, B., Wagener‐Ryczek, S., Baar, T., Heydt, C., Binot, E., Zupp, S., Kron, A., Wolf, J., et al. (2018) · Modern Pathology · doi:10.1038/s41379-018-0182-8 · Cited by 24
Willemsen, A. E. C. A. B., Krausz, S., Ligtenberg, M. J. L., Grünberg, K., Groen, H. J. M., Voest, E. E., Cuppen, E. P. J. G., van Laarhoven, H. W. M., & van Herpen, C. M. L. (2019) · British Journal of Cancer · doi:10.1038/s41416-019-0489-3 · Cited by 24
Wu, S., Liao, W., Su, K., Yu, S., Huang, Y.-L., Yu, C., Yang, J. C., & Shih, J. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100140 · Cited by 24
Metadata
- Authors
- Kris, M. G., Johnson, B. E., Berry, L. D., Kwiatkowski, D. J., Iafrate, A. J., Wistuba, I. I., Varella-Garcia, M., Franklin, W. A., Aronson, S. L., Su, P.-F., Shyr, Y., Camidge, D. R., Sequist, L. V., Glisson, B. S., Khuri, F. R., Garon, E. B., Pao, W., Rudin, C., Schiller, J., Haura, E. B., Socinski, M., Shirai, K., Chen, H., Giaccone, G., Ladanyi, M., Kugler, K., Minna, J. D., & Bunn, P. A.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Vanderbilt University (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Colorado Cancer Center Denver, Aurora
- University of Colorado Cancer Center (US)
- The Partners HealthCare Center for Personalized Genetic Medicine, Boston, Massachusetts
- Winship Cancer Institute (US)
- University of California, Los Angeles (US)
- Johns Hopkins University (US)
- The University of Texas Southwestern Medical Center (US)
- Moffitt Cancer Center (US)
- UPMC Hillman Cancer Center (US)
- Medical University of South Carolina (US)
- National Institutes of Health (US)
- Corresponding author
- Kris, Mark G.
- ORCID
- Kris, Mark G.
- Johnson, Bruce E.
- Berry, Lynne D.
- Kwiatkowski, David J.
- Iafrate, A. John
- Wistuba, Ignacio I.
- Shyr, Yu
- Camidge, D. Ross
- Sequist, Lecia V.
- Glisson, Bonnie S.
- Khuri, Fadlo R.
- Garon, Edward B.
- Pao, William
- Rudin, Charles
- Schiller, Joan
- Haura, Eric B.
- Socinski, Mark
- Shirai, Keisuke
- Chen, Heidi
- Giaccone, Giuseppe
- Ladanyi, Marc
- Minna, John D.
- Bunn, Paul A.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2014-05-21
- Volume
- 311
- Issue
- 19
- Pages
- 1998
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- PMC
- PMC4163053
- OpenAlex
- W2065477010
- Semantic Scholar
- 07fff1c9d77fb2b8731d7d86b38c7ac05df654c7
- Cited by
- 1,724
- References
- 69
- Citations by year
- 2026: 55 · 2025: 99 · 2024: 101 · 2023: 116 · 2022: 164 · 2021: 171 · 2020: 173 · 2019: 137 · 2018: 186 · 2017: 162 · 2016: 173 · 2015: 146 · 2014: 37
- FWCI
- 138.25
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- JAMA (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR000124)
- National Cancer Institute (RC2CA148394, K23CA149079, P01CA129243, 1RC2CA148394‐010, P50CA058187, P30CA008748, P30CA016672, P30CA046934)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
- Keywords
- lung adenocarcinoma, oncogenic drivers, targeted therapy, multiplex genotyping, KRAS, EGFR, ALK rearrangement, BRAF, PIK3CA, ERBB2, MET amplification, NRAS, MEK1, AKT1, metastatic lung cancer, survival, genotype-directed therapy, clinical trial recruitment
- MeSH terms
- Adenocarcinoma of Lung, Adenocarcinoma, Aged, Female, Genotype, Humans, Lung Neoplasms, Male, Middle Aged, Proto-Oncogenes, Survival Analysis, Sequence Analysis, DNA, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization, Molecular Targeted Therapy, Multiplex Polymerase Chain Reaction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-06, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-06 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
